DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/lkzjz9/vaginal_atrophy)
has announced the addition of the “Vaginal
Atrophy (Atrophic Vaginitis) – Pipeline Review, H2 2015” report
to their offering.
This report provides comprehensive information on the therapeutic
development for Vaginal Atrophy (Atrophic Vaginitis), complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic
development for Vaginal Atrophy (Atrophic Vaginitis) and special
features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Allergan Plc
- EndoCeutics, Inc.
- Foamix Pharmaceuticals Ltd.
- Ligand Pharmaceuticals, Inc.
- Pantarhei Bioscience BV
- Peptonic medical AB
- RestorGenex Corporation
- TherapeuticsMD Inc.
- estradiol hemihydrate
- lasofoxifene tartrate
For more information visit http://www.researchandmarkets.com/research/lkzjz9/vaginal_atrophy
Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716